Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

HR Summit, one of the most important events dedicated to the human resources industry in Transylvania, will take place under ...

Novo Nordisk is investing further in obesity and metabolic disease, signing a deal to use Ascendis Pharma’s delivery ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ascendis Pharma, and Ultragenyx Pharmaceutical. According to TipRanks, Ahmad ...

Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.

Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Moreover, they may have significant fluctuations and high peak-to-trough ratios, requiring daily subcutaneous injections. Ascendis Pharma’s (ASND) Palopegteriparatide is a once-daily PTH replacement ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...